CoChat

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells

Open access

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Clinical trials of Chimeric Antigen Receptor (CAR) T cells manufactured from autologous peripheral blood mononuclear cell (PBMC) concentrates for the treatment of hematologic malignancies have been promising, but CAR T cell yields have been variable. This variability is due in part to the contamination of the PBMC concentrates with monocytes and granulocytes. METHODS: Counter-flow elutriation allows for the closed system separation of lymphocytes from monocytes and granulocytes. We investigated the use of PBMC concentrates enriched for lymphocytes using elutriation for manufacturing 8 CD19- and 5 GD2-CAR T cell products. RESULTS: When compared to PBMC concentrates, lymphocyte-enriched elutriation fractions contained greater proportions of CD3+ and CD56+ cells and reduced proportions of CD14+ and CD15+ cells. All 13 CAR T cell products manufactured using the elutriated lymphocytes yielded sufficient quantities of transduced CAR T cells to meet clinical dose criteria. The GD2-CAR T cell products contained significantly more T cells and transduced T cells than the CD19-CAR T cell products. A comparison of the yields of CAR T cells produced from elutriated lymphocytes with the yields of CAR T cells previous produced from cells isolated from PBMC concentrates by anti-CD3/CD28 bead selection or by anti-CD3/CD28 bead selection plus plastic adherence found that greater quantities of GD2-CAR T cells were produced from elutriated lymphocytes, but not CD19-CAR T cells. CONCLUSIONS: Enrichment of PBMC concentrates for lymphocytes using elutriation increased the quantity of GD2-CAR T cells produced. These results provide further evidence that CAR T cell expansion is inhibited by monocytes and granulocytes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-017-1160-5

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Quantity of T cells and transduced T cells in GD2-CAR T cell products. GD2-CAR T cells were manufactured over 10 or 11 days using autologous PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead selection plus plastic adherence (n = 5, triangle) and elutriation (n = 5, diamonds). The quantity of CD3 + cells in the final product is shown in a and transduced CD3+ cells in b
Fig. 1 Quantity of T cells and transduced T cells in GD2-CAR T cell products. GD2-CAR T cells were manufactured over 10 or 11 days using autologous PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead selection plus plastic adherence (n = 5, triangle) and elutriation (n = 5, diamonds). The quantity of CD3 + cells in the final product is shown in a and transduced CD3+ cells in bCC BY · PubMed Central
Fig. 2 Quantity of T cells and transduced T cells in CD19-CAR T cell products. CD19-CAR T cells were manufactured over 7–9 days using autologous PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead selection plus plastic adherence (n = 16, triangle) and elutriation (n = 8, diamonds). The quantity of CD3+ cells in the final product is shown in a and transduced CD3+ cells in b
Fig. 2 Quantity of T cells and transduced T cells in CD19-CAR T cell products. CD19-CAR T cells were manufactured over 7–9 days using autologous PBMC concentrates enriched for lymphocytes using one of 3 methods: anti-CD3/CD28 bead selection (n = 6, circles), anti-CD3/CD28 bead selection plus plastic adherence (n = 16, triangle) and elutriation (n = 8, diamonds). The quantity of CD3+ cells in the final product is shown in a and transduced CD3+ cells in bCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 80

Metadata

Authors
Stroncek, D. F., Lee, D. W., Ren, J., Sabatino, M., Highfill, S., Khuu, H., Shah, N. N., Kaplan, R. N., Fry, T. J., & Mackall, C. L.
Affiliations
  • National Institutes of Health (US)
  • University of Virginia (US)
  • National Institutes of Health Clinical Center (US)
  • Parker Institute for Cancer Immunotherapy (US)
Corresponding author
Stroncek, David F.
Venue
Journal of Translational Medicine
Published
2017-03-16
Volume
15
Issue
1
Pages
59-59
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2599193187
Cited by
80
References
16
Citations by year
2026: 4 · 2025: 2 · 2024: 9 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 10 · 2019: 11 · 2018: 7 · 2017: 4
FWCI
3.86
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute
  • NIH Clinical Center
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
chimeric antigen receptor T cells, CD19 CAR T cells, GD2 CAR T cells, hematologic malignancies
MeSH terms
Cell Adhesion, Child, Humans, Receptors, Antigen, T-Cell, T-Lymphocytes, Transduction, Genetic, Antigens, CD, Lymphocyte Count, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. https://app.cochat.ai/papers/10.1186/s12967-017-1160-5
The paper
Stroncek, D. F., Lee, D. W., Ren, J., Sabatino, M., Highfill, S., Khuu, H., Shah, N. N., Kaplan, R. N., Fry, T. J., & Mackall, C. L. (2017). Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells. Journal of Translational Medicine. https://doi.org/10.1186/s12967-017-1160-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.